We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Antibacterial Coating Could Reduce Suture Infections

By HospiMedica International staff writers
Posted on 10 Sep 2012
A newly developed antibacterial coating for surgical sutures is almost 1,000 times more effective than the most widely used commercial coating. More...


Researchers at the University of Massachusetts (UMass; Amherst, USA) have developed a new bactericidal surgical suture coating based on poly[(aminoethyl methacrylate)-co-(butyl methacrylate)] (PAMBM), an amphiphilic polymer inspired by antimicrobial peptides. PAMBM was evaluated in a variety of polymer blends using the Japanese Industrial Standard (JIS) method and showed excellent antimicrobial activity at a low concentration (0.5 wt %), using a similar antimicrobial coating formula to commercial Vicryl (polyglactin 910) Plus sutures, a product of Ethicon (Somerville, NJ, USA). Disk samples of the coating material containing PAMBM effectively killed bacteria (98% reduction at 0.75 wt %).

Further assays of the same disk samples showed an increasing zone of inhibition with increasing concentration of PAMBM. Finally, the PAMBM-containing coating was applied to sutures, and the morphology of the coating surface was characterized by scanning electron microscope (SEM), along with Vicryl and uncoated sutures. The PAMBM-containing sutures killed bacteria more effectively (3 log10 reduction at 2.4 wt %) than Vicryl Plus sutures (0.5 log10 reduction). The study was published on August 21, 2012, in Langmuir.

“Infection at the site of surgical incisions is one of the most common postsurgical complications that keep patients hospitalized longer and boost hospital bills,” said lead author Prof. Gregory Tew, PhD, of the department of polymer science & engineering. “As bacterial resistance to current agents continues to increase and with resistance to triclosan now documented, the discovery of new antimicrobial agents that remain active in biomedical device coatings is essential.”

The most common antibiotic coating contains triclosan, but its use in many consumer products over the years has led to the emergence of strains of bacteria that shrug off its effects. Triclosan also can be absorbed into the body, raising concerns about possible adverse health effects. Another downside to triclosan is that it slows the growth of bacteria, but does not actually kill those already present.

Related Links:

University of Massachusetts
Ethicon




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.